With Another Pharma Update, Possiblity of Vaccine in Near Future Seems More Promising

After good news yesterday from AstraZeneca’s (AZN) camp on the company’s seal of approval from the EU and what that could mean for the potential roll-out of its coronavirus vaccine, another big pharmaceutical name comes reveals a critical vaccine update. This past July, Moderna (MRNA) launched its 30,000-person, late-stage, clinical trial in the U.S. testing the

Read More ›

Despite Halting Vaccine Trials, Johnson & Johnson Delivers Strong Earnings and Forecast

In the heat of a race with rivals such as Pfizer (PFE), Moderna (MRNA) and AstraZeneca (AZN) to develop a safe and effective vaccine for the coronavirus, Johnson & Johnson (JNJ) provided shareholders with strong insight on how the company has held up through uncertainty. This morning, the pharmaceutical powerhouse reported third-quarter earnings which beat

Read More ›

GenMark Gets Approval on Test that Distinguishes Between Flu, COVID-19 and More

More great news broke yesterday afternoon on the virus diagnosis front, which has sent investors running to their brokers and trading apps. Yesterday, the lab test manufacturer GenMark Diagnostics (GNMK) announced it was granted emergency use authorization by the FDA for its rapid molecular test that can distinguish between more than 20 different viruses and bacteria, including

Read More ›

Kamala Harris Helps Cannabis Industry Climb Back After Stagnant Growth

Ok, let’s be blunt (sorry). In a year defined by quarantines, lockdowns and record food-delivery sales, one could easily the stars would have aligned to send cannabis sales sky high (sorry, again). Instead, the industry finds itself riddled with regulatory delays, slower-than-expected retail store openings, and a persistently strong black market have all weighed on

Read More ›

Market Overview